Welcome to our dedicated page for Amicus Therapeut SEC filings (Ticker: FOLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amicus Therapeutics filings document the former public company’s rare-disease biotechnology business, common stock registration, operating results, governance matters, shareholder voting disclosures, material agreements, risk factors, clinical or regulatory updates, and capital-structure information. The filing record includes Form 8-K reports for quarterly results, corporate updates, and material events tied to its business and securities.
Later filings document Amicus Therapeutics’ completed merger, its survival as a wholly owned subsidiary of BioMarin Pharmaceutical Inc., the removal of its common stock from Nasdaq listing through Form 25, and the termination or suspension of Exchange Act reporting obligations through Form 15. These documents record the company’s transition from a Nasdaq-listed issuer to a subsidiary within BioMarin.
Amicus Therapeutics ownership update: Vanguard Capital Management reports beneficial ownership of 16,350,837 shares of common stock, representing 5.20% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over 16,350,837 shares and sole voting power for 2,327,280 shares. The form clarifies the reported holdings reflect securities managed across Vanguard Capital Management LLC and specified affiliates.
AMICUS THERAPEUTICS, INC. director Craig A. Wheeler disposed of his equity in connection with the acquisition of Amicus by BioMarin Pharmaceutical Inc. Each reported transaction reflects a disposition to the issuer tied to consummation of the merger.
Wheeler surrendered 84,631 shares of Common Stock at $14.50 per share and no Common Stock remained directly owned afterward. He also disposed of multiple fully vested stock option awards, each cancelled and converted into a cash right based on the $14.50 per share merger price minus the option’s exercise price, multiplied by the shares underlying each option grant.
The cancelled options covered various exercise prices, including $5.96, $8.55, $10.27, $10.71, $12.00, $12.62, $12.81, $8.60 and $6.71 per share, with expiration dates ranging from 2026 to 2035. Following these actions, Wheeler no longer held Common Stock or the reported options directly.
Amicus Therapeutics director Margaret G. McGlynn reported disposing of her equity positions in connection with the consummation of the acquisition of Amicus by BioMarin Pharmaceutical Inc. She surrendered 94,631 shares of Common Stock, including 31,000 shares and 63,631 restricted stock units that vested in full at closing.
Multiple fully vested stock options were also cancelled and converted into cash. For each option, she became entitled to a cash payment equal to $14.50 per share minus the applicable exercise price, multiplied by the number of option shares. Following these transactions, her reported direct holdings of Common Stock and options are shown as zero.
AMICUS THERAPEUTICS director Burke W. Whitman reported a full disposition of his equity in connection with the acquisition of Amicus by BioMarin Pharmaceutical Inc.
He disposed of 118,598 shares of Common Stock at $14.50 per share, a figure that includes 98,184 common shares and 20,414 restricted stock units that vested in full when the merger closed. Following this transaction, he no longer holds Amicus common stock.
Multiple fully vested stock option awards, each giving the right to buy Amicus common stock at exercise prices between $5.96 and $12.81 per share, were also cancelled at closing. Each option was converted into a cash payment equal to the difference between $14.50 per share and its exercise price, multiplied by the number of shares subject to that option, leaving no remaining Amicus options outstanding for this director.
Amicus Therapeutics director Glenn Sblendorio disposed of his equity stake in connection with the company’s acquisition by BioMarin Pharmaceutical. He surrendered 142,564 shares of Common Stock at $14.50 per share and 20,414 restricted stock units that vested in full at the merger closing.
Multiple fully vested stock option grants covering shares of Common Stock were also cancelled. For each option, Mr. Sblendorio became entitled to a cash payment equal to the excess of $14.50 per share over the option’s exercise price, multiplied by the number of option shares. Following these transactions, the filing shows no remaining direct stock or option holdings.
AMICUS THERAPEUTICS, INC. director Eiry Roberts reported disposing of equity in connection with the consummation of the company’s acquisition by BioMarin Pharmaceutical Inc.
The filing shows a disposition of 76,275 shares of Common Stock at $14.50 per share, tied to the merger consideration. Footnotes state this amount included 55,861 shares of Common Stock and 20,414 restricted stock units, with the restricted stock units vesting in full at closing of the merger.
Multiple fully vested stock option grants were also disposed of to the issuer and converted into a cash right. These covered 74,872, 42,467, 30,474, 45,423 and 40,625 underlying shares at exercise prices ranging from $5.96 to $12.62 per share. For each option, the holder became entitled to a cash payment equal to the excess of $14.50 per share over the applicable exercise price, multiplied by the number of shares subject to that option. Following these transactions, the reporting person shows 0 shares and 0 options held in this filing.
Amicus Therapeutics director Lynn Dorsey Bleil reported disposing of her equity in connection with the acquisition of Amicus by BioMarin Pharmaceutical Inc. In the transaction, she disposed of 113,941 shares of Common Stock at $14.50 per share and her holdings in this filing fell to zero.
The footnotes state that the disposition occurred upon consummation of the Merger and that each reported stock option was cancelled and converted into a cash payment based on $14.50 per share minus the applicable exercise price, multiplied by the number of option shares. The filing indicates that each option was fully vested or vested in full in connection with the Merger.